Value Creators: Revenio
Translation: Original report published in Finnish on 10/1/2024 at 12:15 noon EEST.
In the Value Creators concept, we highlight companies that have created substantial shareholder value. The reports do not include forecasts; they are based solely on historical data and key figures derived from it.
We evaluate companies based on the following indicators:
- Revenue development
- Operating profit development and profitability (%)
- Return on capital (%)
- Cash flow generated from operations
- Share price development and historical valuations
- Data is primarily sourced from Bloomberg
We look at the long-term development and all figures are presented with the time series 2014-2023. The reports do not constitute investment recommendations.
In this report, we introduce Revenio - a global leader in ophthalmic equipment and software solutions, with a focus on eye care solutions.
Revenio Group
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Read more on company pageKey Estimate Figures08.08.2024
2023 | 24e | 25e | |
---|---|---|---|
Revenue | 96.6 | 105.2 | 120.9 |
growth-% | -0.45 % | 8.90 % | 14.97 % |
EBIT (adj.) | 28.5 | 28.6 | 36.9 |
EBIT-% (adj.) | 29.53 % | 27.16 % | 30.55 % |
EPS (adj.) | 0.80 | 0.83 | 1.09 |
Dividend | 0.38 | 0.40 | 0.57 |
Dividend % | 1.51 % | 1.49 % | 2.14 % |
P/E (adj.) | 31.50 | 32.11 | 24.40 |
EV/EBITDA | 22.03 | 21.68 | 16.71 |